TAK PAUL PETER (President & CEO) sold 71.2% of their position (280.25K shares) of CANDEL THERAPEUTICS, INC. on the open market
Open‑market sale worth $3.16M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 9/11/2026ACC: 0001873905-26-000002
DirectorOfficer· President & CEO
Since Jul 2021
-280.25K
Net shares
Net seller
$3.16M
Total sold
2
Open market trades
0B · 2S
4
Total transactions
125K acquired · 405.25K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+125K
Price / share
$1.55
Trade value
$193.75K
% of position
46.5%
9/10/2026
268.57K→393.57K
Common Stock
Direct
Shares
−220.87K
Price / share
$11.50
Trade value
$2.54M
% of position
56.1%
9/10/2026
393.57K→172.70K
Common Stock
Direct
Shares
−59.38K
Price / share
$10.46
Trade value
$620.89K
% of position
34.4%
9/11/2026
172.70K→113.32K
Total
Net shares
−155.25K
Net value
-$2.97M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/10/2026 | M · Option Exercise | +125K | $1.55 | $193.75K | 46.5% | 268.57K | 393.57K |
| Common Stock Direct | 9/10/2026 | S · Sale | −220.87K | $11.50 | $2.54M | 56.1% | 393.57K | 172.70K |
| Common Stock Direct | 9/11/2026 | S · Sale | −59.38K | $10.46 | $620.89K | 34.4% | 172.70K | 113.32K |
| Total | −155.25K | -$2.97M | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
125K shares
Shares
−125K
Strike price
1.55
Held after
1.64M
Exercisable
—
9/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock125K shares | 9/10/2026 | M · Option Exercise | −125K | 1.55 | — | 1.64M |